"The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report
Name:
Publisher version
UMass Chan Affiliations
Department of Medicine, Division of Pulmonary, Allergy and Critical Care MedicineDepartment of Microbiology and Physiological Systems
Document Type
Journal ArticlePublication Date
2017-06-14Keywords
Immune evasionMycobacterium tuberculosis
tuberculosis
vaccine
Bacterial Infections and Mycoses
Immunology of Infectious Disease
Immunoprophylaxis and Therapy
Infectious Disease
Metadata
Show full item recordAbstract
Tuberculosis (TB) is the major cause of death from infectious diseases around the world, particularly in HIV infected individuals. TB vaccine design and development have been focused on improving Bacille Calmette-Guerin (BCG) and evaluating recombinant and viral vector expressed Mycobacterium tuberculosis (Mtb) proteins, for boosting BCG-primed immunity, but these approaches have not yet yielded significant improvements over the modest effects of BCG in protecting against infection or disease. On March 7-8, 2016, the National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop on "The Impact of Mtb Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" with the goal of defining immune mechanisms that could be targeted through novel research approaches, to inform vaccine design and immune therapeutic interventions for prevention of TB. The workshop addressed early infection events, the impact of Mtb evolution on the development and maintenance of an adaptive immune response, and the factors that influence protection against and progression to active disease. Scientific gaps and areas of study to revitalize and accelerate TB vaccine design were discussed and prioritized. These included a comprehensive evaluation of innate and Mtb-specific adaptive immune responses in the lung at different stages of disease; determining the role of B cells and antibodies (Abs) during Mtb infection; development of better assays to measure Mtb burden following exposure, infection, during latency and after treatment, and approaches to improving current animal models to study Mtb immunogenicity, TB disease and transmission.Source
Vaccine. 2017 Jun 14;35(27):3433-3440. doi: 10.1016/j.vaccine.2017.04.007. Epub 2017 May 2. Link to article on publisher's site